Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Amer H. Zureikat, Mordechai Rabinowitz, Herbert J. Zeh, Savreet Sarkaria, Melissa E. Hogg, Georgios I. Papachristou, John Nasr, Kenneth K. Lee, Jennifer Chennat, Wolfgang H. Schraut, Mazen S. Zenati, Steve J. Hughes, Adam Slivka, Michael K. Sanders, Andres Gelrud, Rohit Das, A. James Moser, Asif Khalid, Alessandro Paniccia, Samer AlMasri
Publikováno v:
Surgical Endoscopy. 36:621-630
Treatment of pancreaticobiliary pathology following Roux-en-Y gastric bypass (RYGB) poses significant technical challenges. Laparoscopic-assisted endoscopic retrograde cholangiopancreatography (LA-ERCP) can overcome those anatomical hurdles, allowing
Autor:
James A. Brown, Richard L. Simmons, Amer H. Zureikat, Mazen S. Zenati, Melissa E. Hogg, Jae P. Jung, Amr I. Al Abbas, Herbert J. Zeh
Publikováno v:
HPB. 23:144-153
Background Cholangitis due to anastomotic stricture of the hepaticojejunostomy (HJ) following pancreaticoduodenectomy (PD), while uncommon, adversely affects postoperative quality-of-life. While prior studies have identified patient-related risk fact
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Melissa E. Hogg, Amir A. Borhani, Herbert J. Zeh, Juliana Tobler, Ahmad Hamad, Mazen S. Zenati, Amer H. Zureikat, Patrick R. Varley, A. Klobuka
Publikováno v:
HPB. 21:695-701
We sought to investigate whether robotic pancreatoduodenectomy (RPD) mitigates adverse outcomes in patients with high-risk morphometric features compared to the open approach (OPD).Morphometric parameters for RPD and OPDs were measured by two blinded
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Deepa Magge, Amer H. Zureikat, Ahmad Hamad, Mazen S. Zenati, Herbert J. Zeh, Melissa E. Hogg, Caroline J. Rieser
Publikováno v:
HPB. 20:1172-1180
NSQIP data show that half of distal pancreatectomies (DP) are performed by a minimally invasive approach (MIS). Advantages have been demonstrated for MIS DP, yet comparative cost data are limited. Outcomes and cost were compared in patients undergoin